David Meyer1, Alasdair Coles2, Pedro Oyuela3, Annie Purvis4, David H Margolin5. 1. Triad Neurological Associates, Cornerstone Health Care, 145 Kimel Park Drive, Suite 100, Winston Salem, NC 27103, USA. Electronic address: David.Meyer@cornerstonehealthcare.com. 2. Department of Neurosciences, University of Cambridge, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0QQ, UK. Electronic address: ajc1020@medschl.cam.ac.uk. 3. Genzyme Corporation, 500 Kendall Street, Cambridge, MA 02142, USA. Electronic address: pedro.oyuela@genzyme.com. 4. Genzyme Corporation, 500 Kendall Street, Cambridge, MA 02142, USA. Electronic address: annie.purvis@genzyme.com. 5. Genzyme Corporation, 500 Kendall Street, Cambridge, MA 02142, USA. Electronic address: david.margolin@genzyme.com.
Abstract
OBJECTIVE: To report a case of anti-glomerular basement membrane disease (anti-GBM disease) during alemtuzumab treatment of a relapsing-remitting multiple sclerosis (RRMS) patient. DESIGN: Case report. SETTING: Outpatient neurology research protocol. PATIENT: A 35-year-old white female receiving alemtuzumab for RRMS in a clinical research protocol developed symptoms leading to diagnosis of anti-GBM disease. MAIN OUTCOME MEASURE: Patient response to the treatment of anti-GBM disease and RRMS. RESULTS: Early identification and treatment of anti-GBM disease resolved clinical symptoms and preserved renal function. Alemtuzumab treatment of RRMS resolved initial MS symptoms and appears to have controlled active disease to date. CONCLUSION: Close monitoring for potential side effects of alemtuzumab treatment in RRMS resulted in a positive outcome when anti-GBM disease was recognized and treated early.
OBJECTIVE: To report a case of anti-glomerular basement membrane disease (anti-GBM disease) during alemtuzumab treatment of a relapsing-remitting multiple sclerosis (RRMS) patient. DESIGN: Case report. SETTING:Outpatient neurology research protocol. PATIENT: A 35-year-old white female receiving alemtuzumab for RRMS in a clinical research protocol developed symptoms leading to diagnosis of anti-GBM disease. MAIN OUTCOME MEASURE: Patient response to the treatment of anti-GBM disease and RRMS. RESULTS: Early identification and treatment of anti-GBM disease resolved clinical symptoms and preserved renal function. Alemtuzumab treatment of RRMS resolved initial MS symptoms and appears to have controlled active disease to date. CONCLUSION: Close monitoring for potential side effects of alemtuzumab treatment in RRMS resulted in a positive outcome when anti-GBM disease was recognized and treated early.